Search Results - "Jeng, Wen‐Juei"

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients—Authors' reply.

Authors: Lin, Hsin‐Che Jeng, Wen‐Juei Yang, Hwai‐I

Source: Alimentary Pharmacology & Therapeutics. Jun2024, Vol. 59 Issue 11, p1459-1461. 3p.

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply.

Authors: Lin, Hsin‐Che Jeng, Wen‐Juei Yang, Hwai‐I

Source: Alimentary Pharmacology & Therapeutics. Jun2024, Vol. 59 Issue 12, p1618-1619. 2p.

Letter: sPD‐1 as a predictor for HBsAg seroclearance—shed light on inactive carriers with chronic hepatitis B. Authors' reply.

Authors: Jeng, Wen‐Juei Pan, Mei‐Hung Yang, Hwai‐I

Source: Alimentary Pharmacology & Therapeutics. Apr2022, Vol. 55 Issue 8, p1057-1058. 2p. 1 Graph.

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate.

Authors: Jeng, Wen‐Juei Liaw, Yun‐Fan

Source: Alimentary Pharmacology & Therapeutics. Apr2025, Vol. 61 Issue 8, p1422-1423. 2p.

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.

Authors: Lin, Hsin‐Che Jeng, Wen‐Juei Liu, Jessica et al.

Source: Alimentary Pharmacology & Therapeutics. Apr2024, Vol. 59 Issue 8, p993-1002. 10p.

Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B.

Authors: Hu, Hui‐Han Jeng, Wen‐Juei Pan, Mei‐Hung et al.

Source: Alimentary Pharmacology & Therapeutics. Mar2022, Vol. 55 Issue 5, p558-567. 10p. 3 Charts, 3 Graphs.

Retraction Note: Efficacy of a multidimensional self-management intervention on low-education women with metabolic syndrome: a cluster randomized controlled trial.

Authors: Chang, Shu-Hung Chang, Yi-Ya Jeng, Wen-Juei et al.

Source: Scientific Reports. 12/10/2024, Vol. 14 Issue 1, p1-1. 1p.

Author Correction: Efficacy of a multidimensional self-management intervention on low-education women with metabolic syndrome: a cluster randomized controlled trial.

Authors: Chang, Shu-Hung Chang, Yi-Ya Jeng, Wen-Juei et al.

Source: Scientific Reports. 7/3/2023, Vol. 13 Issue 1, p1-1. 1p.

Soluble form of CTLA‐4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.

Authors: Teng, Wei Jeng, Wen‐Juei Chen, Wei‐Ting et al.

Source: Cancer Medicine. Oct2022, Vol. 11 Issue 20, p3786-3795. 10p.

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection.

Authors: Liu, Yen‐Chun Jeng, Wen‐Juei Chien, Rong‐Nan

Source: Alimentary Pharmacology & Therapeutics. Oct2023, Vol. 58 Issue 7, p731-732. 2p.

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays.

Authors: Jeng, Wen-Juei Chen, Chien-Hung Wang, Yi-Wen et al.

Source: Virology Journal. 3/31/2022, Vol. 19 Issue 1, p1-8. 8p.

Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy.

Authors: Liaw, Yun‐Fan Jeng, Wen‐Juei Chien, Rong‐Nan

Source: Liver International. Apr2022, Vol. 42 Issue 4, p945-946. 2p. 1 Chart.

Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients.

Authors: Liu, Yen‐Chun Jeng, Wen‐Juei

Source: Alimentary Pharmacology & Therapeutics. Mar2023, Vol. 57 Issue 5, p577-578. 2p.

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals.

Authors: Liu, Yen‐Chun Jeng, Wen‐Juei Peng, Chien‐Wei et al.

Source: Alimentary Pharmacology & Therapeutics. Mar2024, Vol. 59 Issue 6, p762-773. 12p.

Fibrosis-4 Score Is Associated with Mortality in Hemodialysis Patients with Chronic Viral Hepatitis: A Retrospective Study.

Authors: Liu, Hao-Hsuan Yen, Chieh-Li Jeng, Wen-Juei et al.

Source: Diagnostics (2075-4418). Sep2024, Vol. 14 Issue 18, p2048. 13p.

Letter: the probability of predicting HBV‐specific CD8+ cell response derived from HLA‐A2+ may not closely predict functional cure in Asian patients who stop nucleoside analogues.

Authors: Liu, Yen‐Chun Jeng, Wen‐Juei

Source: Alimentary Pharmacology & Therapeutics. Oct2022, Vol. 56 Issue 8, p1310-1311. 2p. 1 Chart.

Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg‐negative chronic hepatitis B?

Authors: Liu, Yen‐Chun Jeng, Wen‐Juei

Source: Alimentary Pharmacology & Therapeutics. Aug2022, Vol. 56 Issue 3, p544-545. 2p.

Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies.

Authors: Liu, Yen‐Chun Jeng, Wen‐Juei Peng, Chien‐Wei et al.

Source: Liver International. Mar2022, Vol. 42 Issue 3, p551-560. 10p. 4 Charts, 2 Graphs.

Discrepant range of sPD‐1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death‐1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B.

Authors: Jeng, Wen‐Juei Yang, Hwai‐I

Source: Journal of Viral Hepatitis. Jul2019, Vol. 26 Issue 7, p930-930. 1p.

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance.

Authors: Keng, Hsiang‐Ting Liu, Yen‐Chun Jeng, Wen‐Juei

Source: Alimentary Pharmacology & Therapeutics. Jun2026, p1. 2p.